Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus. Cytoplasm. Cleavage furrow. Note=Cell-cycle-dependent association with the centrosome. Colocalizes with a subpopulation of microtubules. Does not associates with microtubules during mitosis but reassociates with microtubules during cytokinesis. Localizes to the central portions of a small subset of microtubules in interphase cells and a subpopulation of microtubules in the cleavage furrow, not present in the mitotic spindle. |
Domain |
PF00041 Fibronectin type III domain PF00622 SPRY domain |
Function |
May be involved in microtubule organization and stabilization. |
Biological Process |
GO:0007067 mitotic nuclear division |
Molecular Function | - |
Cellular Component |
GO:0005874 microtubule GO:0032153 cell division site GO:0032154 cleavage furrow GO:0032155 cell division site part GO:0097610 cell surface furrow |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between FSD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of FSD1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of FSD1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of FSD1 in various data sets.
|
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FSD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FSD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FSD1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FSD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of FSD1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between FSD1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | FSD1 |
Name | fibronectin type III and SPRY domain containing 1 |
Aliases | MGC3213; fibronectin type 3 and SPRY domain containing 1; GLFND; MID1-related protein 1; fibronectin type 3 ...... |
Chromosomal Location | 19p13.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting FSD1 collected from DrugBank database. |
There is no record. |